What are the best treatments for Pulmonary Fibrosis?

The current standard of care for Pulmonary Fibrosis focuses on slowing disease progression through antifibrotic medications, supplemental oxygen, and specialized pulmonary rehabilitation.

Pharmacological Interventions

For patients diagnosed with idiopathic Pulmonary Fibrosis, the two FDA-approved antifibrotic medications are nintedanib (Ofev) and pirfenidone (Esbriet). These drugs do not reverse existing scarring, but clinical trials have consistently demonstrated that they can slow the decline in forced vital capacity (FVC). Because Pulmonary Fibrosis manifests differently in every individual, your physician will evaluate your specific lung function, comorbidities, and side-effect profile to determine if these therapies are appropriate for your treatment plan.

Non-Pharmacological and Supportive Care

Management of Pulmonary Fibrosis extends beyond medication. Pulmonary rehabilitation is a cornerstone of care, involving physical therapy and breathing exercises to improve exercise tolerance and quality of life. For patients with low blood oxygen levels, supplemental oxygen therapy is essential to reduce the workload on the heart and decrease breathlessness. In advanced cases, or for those who meet specific clinical criteria, lung transplantation remains the only potential life-extending surgical intervention.

Multidisciplinary Care and Research

Because Pulmonary Fibrosis is a complex, systemic condition, it is best managed by a multidisciplinary team. This team should ideally include a pulmonologist specializing in interstitial lung disease (ILD), a radiologist, a pathologist, and a thoracic surgeon. Regarding the future of care, clinical research is currently investigating novel therapies, including monoclonal antibodies and gene-targeted treatments, aimed at stopping or reversing the fibrotic process. You may wish to discuss active clinical trials listed on registries such as ClinicalTrials.gov with your medical team to see if you are a candidate for emerging research.

Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Pulmonary Fibrosis


• Orphanet: Idiopathic Pulmonary Fibrosis


• Pulmonary Fibrosis Foundation (PFF): Treatment and Management Guidelines